Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower CA, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M.
Villa D, et al.
Blood Adv. 2022 Sep 27;6(18):5285-5294. doi: 10.1182/bloodadvances.2022007371.
Blood Adv. 2022.
PMID: 35439293
Free PMC article.
Clinical Trial.
The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patien …
The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R- …